Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial

• Glavni autori: Leilani Sanchez (Autor), Osamu Matsuoka (Autor), Satoshi Inoue (Autor), Takahiro Inoue (Autor), Ya Meng (Autor), Takahiro Nakama (Autor), Kumiko Kato (Autor), Aseem Pandey (Autor), Lee-Jah Chang (Autor)
• Format: Knjiga
• Izdano: Taylor & Francis Group, 2020-04-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

A trivalent high-dose inactivated influenza vaccine has been licensed in healthy adults ≥65 years of age and provides better protection against influenza infection and related complications than trivalent standard-dose vaccine. This phase I/II clinical trial (NCT03233217), conducted at two sites in...